世界の眼疾患治療薬分野における主要な製薬企業分析

visiongainが発行した調査報告書(VGAIN503041)
◆英語タイトル:Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025
◆商品コード:VGAIN503041
◆発行会社(リサーチ会社):visiongain
◆発行日:2015年2月
◆ページ数:242
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Sigle UserGBP1,799 ⇒換算¥266,252見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算¥443,852見積依頼/購入/質問フォーム
Site License(全社内共有可)GBP4,999 ⇒換算¥739,852見積依頼/購入/質問フォーム
※visiongain社発行の調査レポートは、Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。

販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongain社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。visiongain社の概要及び新刊レポートはこちらでご確認いただけます。

当調査レポートでは、世界の眼疾患治療薬分野における主要な製薬企業について調査・分析し、以下の構成でお届けいたします。

・レポートの概要
・イントロダクション
・眼疾患治療薬の世界市場規模
・アメリカの主要な眼疾患治療薬メーカー分析
・ヨーロッパの主要な眼疾患治療薬メーカー分析
・アジア太平洋の主要な眼疾患治療薬メーカー分析
・新興企業分析
・専門家の見解
・結論
【レポートの概要】

New study shows you commercial prospects for leading ophthalmic drug companies
What does the future hold for top companies in the pharma ophthalmic industry? Visiongain’s brand new report shows you potential revenues to 2025, assessing data, trends, opportunities and prospects there.

Our 242-page report provides 185 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market. You will see financial results, interviews, trends, opportunities, and revenue predictions. Much opportunity remains in this growing pharma market.

Forecasts from 2015-2025 and other analyses show you commercial prospects
Besides revenue forecasting to 2025, our new study provides you with recent results, growth rates, and market shares. There you find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT and Porter’s Five Forces Analysis), company profiles and commercial developments. Read the full transcripts of 3 exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales, including:
• Dr Leigh Hsu, Vice President, Corporate Development & Strategy, Lpath
• Dan Myers, President and CEO, Alimera Sciences
• Vanda Pharmaceuticals

Discover sales predictions for the world market and submarkets
Overall we estimate the world revenue for ophthalmic drugs reached $21,513m in 2014. We predict revenue growth from 2015 to 2025. Increasing prevalence of ophthalmic diseases due to demographic trends, expansion of healthcare in developing economies, relatively rich pipelines especially in retinal disorders, large unmet needs in the glaucoma and dry eye markets are set to drive sales in the ophthalmic drugs market to 2025.

Along with revenue prediction for the overall world market, you see forecasts to 2025 for these five submarkets:
• Retinal disorders drugs
• Allergic, inflammatory and infective drugs
• Glaucoma drugs
• Dry eye drugs
• Other ophthalmic drugs

In addition we provide market attractiveness forecast analysis for the leading segments in 2019 and 2025. You gain competitive advantages by understanding the dynamics, opportunities and challenges facing the ophthalmic drugs market.

Leading companies and potential for market growth
Our ophthalmic leader series report shows you a ranking for the top 25 ophthalmic drug manufacturers based on revenues and R&D progress. Additionally, the report provides you with in-depth analysis and profiles for the top 10 leading companies in the ophthalmic drugs market including:
• Novartis
• Allergan
• Roche
• Valeant
• Regeneron
• Santen
• Bayer
• Pfizer
• Senju
• Akorn

A company profile gives you the following information:
• Total ophthalmic drugs revenue forecasts to 2025
• Revenue forecasts for individual leading ophthalmic drugs to 2025
• Market share in the global ophthalmic drugs market forecast to 2025
• Ophthalmic drugs revenue rankings
• Recent financial results
• Ophthalmic drugs pipeline analysis
• SWOT analysis
• Discussion of a company’s activities and outlook
• Assessment of recent developments – mergers and acquisitions (M&A), new products, and collaborations, including alliances, partnerships and joint ventures

Moreover, our report provides information on 27 additional leading companies in the ophthalmic drugs market. You see outlooks for a wide range of companies, from multinationals to emerging specialists in the eye disorders field. Find developments for treating visual disorders and sight loss.

See revenue forecasts for products
How will leading ophthalmic drugs perform to 2025 at world level? Our study forecasts sales of more than 25 products, including these brands:
• Lucentis
• Eylea
• Avastin
• Restasis
• Lumigan and Ganfort
• Xalatan/Xalacom
• Travatan/Travatan Z and DuoTrav
• Alphagan/Alphagan P and Combigan
• Refresh brand products
• Pataday
• Vigamox

【レポートの目次】

1. Report Overview
1.1 Global Ophthalmic Drugs Market Overview
1.2 Global Ophthalmic Drugs Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Visiongain Reports
1.10 About Visiongain

2. Introduction to Ophthalmic Drugs
2.1 The Pharmaceutical Industry: a Very Brief Overview
2.2 The Global Burden of Eye Disease
2.3 Ophthalmic Drugs: Market Segmentation
2.4 Glaucoma: the ‘Silent Thief of Sight’
2.4.1 A Classification of Glaucoma
2.4.1.1 Primary Open-Angle Glaucoma
2.4.1.2 Acute Angle-Closure Glaucoma
2.4.1.3 Congenital Glaucoma
2.4.1.4 Secondary Glaucoma
2.4.1.5 Normal-Tension Glaucoma
2.4.1.6 Ocular Hypertension
2.4.2 Risk Factors for Glaucoma
2.4.3 Diagnosis of Glaucoma
2.4.4 Drug Treatment of Glaucoma
2.4.5 Laser Treatment and Surgery for Glaucoma
2.5 Age-Related Macular Degeneration (AMD)
2.5.1 Dry (non-exudative) AMD
2.5.2 Wet (exudative) AMD
2.5.3 Risk Factors for AMD
2.5.4 Diagnosis of AMD
2.5.5 Treatment of AMD
2.6 Diabetic Retinopathy (DR)
2.6.1 Diagnosis of Diabetic Retinopathy
2.6.2 Treatment of Diabetic Retinopathy
2.7 Ocular Allergy and Allergic Conjunctivitis
2.7.1 Diagnosis of Ocular Allergy
2.7.2 Treatment of Ocular Allergy
2.8 Ocular Inflammatory Disease
2.8.1 Treatment of Ocular Inflammatory Disease
2.9 Eye Infections
2.9.1 Treatment of Eye Infections
2.10 Dry Eye Syndrome
2.10.1 Treatment of Dry Eye Syndrome
2.11 Phases of Clinical Trials
2.12 Currency Exchange Rates in This Report

3. Ophthalmic Drugs: World Market 2015-2025
3.1 The World Ophthalmic Drugs Market in 2014
3.2 World Ophthalmic Drugs Market: Sales Forecast 2015-2025
3.3 Leading Ophthalmic Drugs
3.4 Leading Companies in the Ophthalmic Drugs Market
3.4.1 Top 25 Ophthalmic Drug Manufacturers
3.5 Ophthalmic Drugs Market Segments: Sales Forecasts 2015-2025
3.5.1 Retinal Disorders Drugs Market: Sales Forecast 2015-2025
3.5.2 Allergic, Inflammatory and Infective Drugs Market: Sales Forecast 2015-2025
3.5.3 Glaucoma Drugs Market: Sales Forecast 2015-2025
3.5.4 Dry Eye Drugs Market: Sales Forecast 2015-2025
3.5.5 Other Ophthalmic Drugs Market: Sales Forecast 2015-2025
3.6 How Will Segmental Market Shares Change to 2025?
3.7 CAGR Forecasts of Ophthalmic Drugs Markets From 2014-2025
3.8 Market Attractiveness of Ophthalmic Drugs Markets in 2019
3.9 Market Attractiveness of Ophthalmic Drugs Markets in 2025
3.10 World Ophthalmic Drugs Market: Drivers and Restraints 2015-2025
3.10.1 World Ophthalmic Drugs Market: Analysis of Drivers
3.10.2 World Ophthalmic Drugs Market: Analysis of Restraints

4. Leading US Ophthalmic Drug Manufacturers 2015-2025
4.1 Allergan Overview
4.1.1 Allergan: Ophthalmic Product Portfolio
4.1.1.1 Restasis: Generic Launch in 2015?
4.1.1.2 Restasis: Sales Forecast 2015-2025
4.1.1.3 Lumigan and Ganfort: Marketed in Over 67 Countries
4.1.1.4 Lumigan and Ganfort: Sales Forecast 2015-2025
4.1.1.5 Refresh Brand Products: the Range
4.1.1.6 Refresh Brand Products: Sales Forecast 2015-2025
4.1.1.7 Alphagan/Alphagan P and Combigan: Extended Lifecycle
4.1.1.8 Alphagan/Alphagan P and Combigan: Sales Forecast 2015-2025
4.1.1.9 Acular: New Forms Receiving FDA Approvals
4.1.1.10 Acular: Sales Forecast 2015-2025
4.1.1.11 Ozurdex (Dexamethasone Intravitreal Implant): The First Drug Therapy for Diabetic Macular Oedema
4.1.2 Allergan: Ophthalmic Product Pipeline
4.1.2.1 Novadur (Intravitreal Brimonidine Implant)
4.1.2.2 AGN 208397 (Beclomethasone Intravitreal Injection)
4.1.2.3 Anti-VEGF DARPins (VEGF Inhibitors)
4.1.3 Allergan: Ophthalmic Revenue Forecast 2015-2025
4.1.3.1 Allergan: Ophthalmic Drugs Market Share Forecast 2015-2025
4.1.4 Allergan: SWOT Analysis
4.2 Merck Overview
4.2.1 Merck: Exiting the Ophthalmic Drugs Market
4.2.2 Merck: Ophthalmic Product Pipeline
4.2.3 Merck: Ophthalmic Drugs Sales in 2013 and 2014
4.3 Pfizer Overview
4.3.1 Pfizer: Ophthalmic Product Portfolio
4.3.1.1 Xalatan/Xalacom: First Ophthalmic Blockbuster
4.3.1.2 Xalatan/Xalacom: Sales Forecast 2015-2025
4.3.2 Pfizer: Ophthalmic Product Pipeline
4.3.3 Pfizer: Revenue Forecast 2015-2025
4.3.3.1 Pfizer: Ophthalmic Drugs Market Share Forecast 2015-2025
4.3.4 Pfizer: SWOT Analysis
4.4 Regeneron Overview
4.4.1 Regeneron: Ophthalmic Product Portfolio
4.4.1.1 Eylea: Superior Clinical Outcomes than Lucentis and Avastin?
4.4.1.2 Eylea: US Sales Forecast 2015-2025
4.4.2 Regeneron: Ophthalmic Product Pipeline
4.4.3 Regeneron: Revenue Forecast 2015-2025
4.4.3.1 Regeneron: Ophthalmic Drugs Market Share Forecast 2015-2025
4.4.4 FDA Approves Zaltrap (aflibercept)
4.4.5 Eylea/Zaltrap and the Davis-Smyth Patent Agreements
4.4.6 Regeneron: SWOT Analysis
4.5 Akorn Overview
4.5.1 Akorn: Ophthalmic Product Portfolio
4.5.1.1 AzaSite: AzaSite Plus and AzaSite Xtra Set to Drive AzaSite Sales
4.5.1.2 AzaSite: Sales Forecast 2015-2025
4.5.1.3 Zioptan: Acquired from Merck
4.5.1.4 Zioptan: Sales Forecast 2015-2025
4.5.1.5 Cosopt/Cosopt PF: Acquired from Merck
4.5.1.6 Cosopt/Cosopt PF: US Sales Forecast 2015-2025
4.5.2 Akorn: Revenue Forecast 2015-2025
4.5.2.1 Akorn: Ophthalmic Drugs Market Share Forecast 2015-2025
4.5.3 Akorn: SWOT Analysis

5. Leading European Ophthalmic Drug Manufacturers 2015-2025
5.1 Bayer Overview
5.1.1 Eylea: non-US Sales Forecast 2015-2025
5.1.2 Bayer: Revenue Forecast 2015-2025
5.1.2.1 Bayer: Ophthalmic Drugs Market Share Forecast 2015-2025
5.2 Novartis (including Alcon) Overview
5.2.1 Novartis: Ophthalmic Product Portfolio
5.2.1.1 Lucentis: Best-Selling Ophthalmic Drug in 2014
5.2.1.2 Lucentis: Non-US Sales Forecast 2015-2025
5.2.1.3 Travatan/Travatan Z and DuoTrav: DuoTrav Awaiting US Approval
5.2.1.4 Travatan/Travatan Z and DuoTrav: Sales Forecast 2015-2025
5.2.1.5 Vigamox: Competes with Alcon’s Moxeza
5.2.1.6 Vigamox: Sales Forecast 2015-2025
5.2.1.7 Azopt: Marketed in Major Markets
5.2.1.8 Azopt: Sales Forecast 2015-2025
5.2.1.9 Jetrea: Sales Revenues Fall Short
5.2.1.10 Jetrea: Non-US Sales Forecast 2015-2025
5.2.2 Novartis: Ophthalmic Product Pipeline
5.2.2.1 Finafloxacin (MerLion Pharmaceuticals/Novartis)
5.2.2.2 AKB 9778 (Aerpio Therapeutics)
5.2.3 Novartis: Revenue Forecast 2015-2025
5.2.3.1 Novartis: Ophthalmic Drugs Market Share Forecast 2015-2025
5.2.4 Novartis: SWOT Analysis
5.3 Roche Overview
5.3.1 Roche: Ophthalmic Product Portfolio
5.3.1.1 Lucentis: US Sales Forecast 2015-2025
5.3.1.2 Avastin: Will It Remain Off-Label Use for Wet AMD?
5.3.1.3 Avastin: Sales Forecast 2015-2025
5.3.2 Roche: Ophthalmic Product Pipeline
5.3.2.1 Lampalizumab (RG7417)
5.3.3 Roche: Revenue Forecast 2015-2025
5.3.3.1 Roche: Ophthalmic Drugs Market Share Forecast 2015-2025
5.3.4 Roche: SWOT Analysis
5.3.4.1 Lucentis Granted Fourth Approval in the US

6. Leading Asia-Pacific and Other Ophthalmic Drug Manufacturers 2015-2025
6.1 Santen Overview
6.1.1 Santen: Ophthalmic Product Portfolio
6.1.1.1 Eylea: Japan Sales Forecast 2015-2025
6.1.1.2 Hyalein: Santen’s Best Selling Drug in 2014
6.1.1.3 Hyalein: Sales Forecast 2015-2025
6.1.1.4 Cosopt: Non-US Sales Forecast 2015-2025
6.1.1.5 Tapros/Taflotan: Sales Forecast 2015-2025
6.1.1.6 Diquas: Sales Forecast 2015-2025
6.1.1.7 Cravit: Higher Concentration Showing Significant Efficacy
6.1.1.8 Cravit: Sales Forecast 2015-2025
6.1.1.9 Trusopt: Non-US Sales Forecast 2015-2025
6.1.2 Santen: Ophthalmic Product Pipeline
6.1.3 Santen: Revenue Forecast 2015-2025
6.1.3.1 Santen: Ophthalmic Drugs Market Share Forecast 2015-2025
6.1.4 Santen: SWOT Analysis
6.2 Senju Overview
6.2.1 Senju: Ophthalmic Product Portfolio
6.2.2 Senju: Ophthalmic Product Pipeline
6.2.2.1 Y 39983 (SNJ 1656)
6.2.2.2 Difluprednate (SJE-2079)
6.2.3 Senju: Revenue Forecast 2015-2025
6.2.3.1 Senju: Ophthalmic Drugs Market Share Forecast 2015-2025
6.2.4 Senju: SWOT Analysis
6.3 Valeant Overview
6.3.1 Valeant: Ophthalmic Product Portfolio
6.3.1.1 Timoptic: US Sales Forecast 2015-2025
6.3.1.2 Bromday: New Formulation Released
6.3.1.3 Bromday: Sales Forecast 2015-2025
6.3.2 Valeant: Ophthalmic Product Pipeline
6.3.2.1 Vesneo (BOL 303259-X)
6.3.2.2 MIM-D3 (tyrosine kinase receptor antagonist, Valeant)
6.3.2.3 Brimonidine for Eye Whitening (Valeant)
6.3.3 Valeant: Revenue Forecast 2015-2025
6.3.3.1 Valeant: Ophthalmic Drugs Market Share Forecast 2015-2025
6.3.4 Valeant: SWOT Analysis
6.3.4.1 Valeant’s Acquisition of Bausch and Lomb: Aggressive Expansion?

7. Emerging Ophthalmic Drug Manufacturers in 2015
7.1 Pipeline and Other Companies, 2015
7.2 Abbott: Fenofibrate Approved in Australia for Diabetic Retinopathy
7.3 Acucela
7.4 Aerie Pharmaceuticals
7.5 Aerpio Therapeutics: Developing AKB 9778
7.6 Alimera Sciences
7.6.1 Iluvien Gained Recent FDA Approval
7.6.2 NADPH Oxidase Inhibitors Offer Potential for Dry AMD
7.7 Altheos
7.8 Amakem
7.9 Ampio Pharmaceuticals
7.10 BioDiem
7.10.1 BDM-E: A High-Value Divestment?
7.11 Can-Fite BioPharma/OphthaliX
7.12 Chengdu Kanghong Pharmaceutical
7.13 Eleven Biotherapeutics
7.14 EyeGate Pharmaceuticals
7.15 Gene Signal
7.15.1 Aganirsen: Preventing Corneal Graft Rejection
7.16 GSK
7.16.1 Darapladib for Diabetic Macular Oedema
7.17 Icon Bioscience
7.18 Lpath
7.18.1 iSONEP: Antibodies Against Bioactive Lipids
7.19 MacuCLEAR
7.19.1 MC 1101: a Potential Therapy for Dry AMD
7.20 Neurotech
7.20.1 Renexus (NT 501) for Dry AMD
7.21 Omeros
7.22 Ophthotech
7.22.1 Will Roche Succeed in Acquiring Fovista?
7.22.2 Fovista: Significant Improvement on Lucentis in Phase 2 Trials
7.22.3 Zimura: Complement C5 Inhibitor
7.23 Otsuka Pharmaceutical
7.24 OXiGENE: Developing Zybrestat for Wet AMD
7.25 RXi Pharmaceuticals: Will Bevasiranib Resume Development?
7.26 Shire
7.26.1 Lifitegrast (SHP606) for Dry Eye
7.26.2 Premiplex (SHP607): Preventing Retinopathy of Prematurity
7.27 ThromboGenics
7.27.1 Jetrea (ocriplasmin)
7.27.1.1 Jetrea: US Sales Forecast 2015-2025
7.27.2 TB 403: Anti-Placental Growth Factor

8. Qualitative Analysis of the Ophthalmic Drugs Market 2015-2025
8.1 Porter’s Five Forces Analysis of the Ophthalmic Drugs Market
8.1.1 Rivalry Among Competitors [Medium] 8.1.2 Threat of New Entrants [Low] 8.1.3 Power of Suppliers [Low] 8.1.4 Power of Buyers [Medium] 8.1.5 Threat of Substitutes [Medium]

9. Research Interviews
9.1 Interview with Dan Myers, President and CEO, Alimera Sciences
9.1.1 Alimera Sciences’ Key Products
9.1.2 Expectations for the Launch of Iluvien in the US and EU
9.1.3 Alimera Sciences’ Plans for Growth
9.1.4 Alimera Sciences’ Ophthalmic Pipelines
9.1.5 Challenges in the Ophthalmic Drugs Market
9.1.6 Treatment Change in Retinal Disorders in the Next Decade
9.1.7 Successful Therapies in Ophthalmology in the Next Decade
9.1.8 Trends and Developments in the Ophthalmic Drugs Market
9.2 Interview with Dr. Leigh Hsu, Vice President, Corporate Development and Strategy, Lpath Inc.
9.2.1 Lpath’s Work in Ophthalmology
9.2.2 Progress Update on iSONEP in Clinical Development
9.2.3 Planned Phase 3 Trials in 2015?
9.2.4 Lpath’s Plans for Growth
9.2.5 Main Unmet Needs in Ophthalmology
9.2.6 Promising New Drug Targets in Development
9.2.7 Potential Treatments for Retinal Disorders in the Next Decade
9.2.8 Trends in Ophthalmology: Combination Therapy, Implants, Delivery Methods
9.3 Interview with a Spokesperson for Vanda Pharmaceuticals, Washington DC, US
9.3.1 Commercialising Hetlioz
9.3.2 Future Prospects for Vanda

10. Conclusions
10.1 Ophthalmic Pharmaceuticals: A Growing Niche Market
10.2 The World Ophthalmic Drugs Market in 2014
10.2.1 Leading Ophthalmic Drugs Market Segments
10.2.2 Leading Ophthalmic Drugs
10.2.3 Leading Ophthalmic Drugs Companies
10.3 World Ophthalmic Drugs Market Forecast 2015-2025
10.4 The Future of the Ophthalmic Drugs Market?
10.4.1 Increasing Revenue Concentration among Specialist Companies
10.4.2 The Rise of Generics
10.4.3 Small Companies Can Have a Big Impact
10.4.4 What Will Succeed in the Ophthalmic Drugs Market?

11. Glossary

List of Tables
Table 1.1 Leading Ophthalmic Drugs Market Forecast 2015-2025 ($m, AGR%)
Table 2.1 ICD 10 Classification of Visual Impairment, 2010
Table 2.2 Drug Treatments for Glaucoma, 2015
Table 2.3 Drug Treatments for AMD, 2015
Table 2.4 Drug Treatments for Ocular Allergy, 2015
Table 2.5 Drug Treatments for Ocular Inflammatory Disease, 2015
Table 2.6 Selected Drug Treatments for Eye Infections, 2015
Table 2.7 Clinical Trial Phases
Table 2.8 Currency Exchange Rates, 2013
Table 3.1 World Ophthalmic Drugs Market: Revenue ($m) and Market Share (%) by Segment, 2014
Table 3.2 World Ophthalmic Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 3.3 Top 10 Ophthalmic Drugs: Revenue ($m), Market Share (%), Rank, Active Ingredient and Manufacturer, 2014
Table 3.4 Top 10 Ophthalmic Drug Manufacturers: Ophthalmic Drugs Revenue ($m), Market Share (%), 2014
Table 3.5 Top 25 Ophthalmic Drug Manufacturers: Ophthalmic Drugs Revenue ($m), Leading Pipeline Products, 2014
Table 3.6 World Ophthalmic Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Segment, 2014-2025
Table 3.7 Retinal Disorders Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
Table 3.8 Allergic, Inflammatory and Infective Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
Table 3.9 Glaucoma Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
Table 3.10 Dry Eye Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
Table 3.11 Other Ophthalmic Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
Table 3.12 Market Shares (%) of the Ophthalmic Drugs Market by Segment, 2014, 2019 and 2025
Table 3.13 World Ophthalmic Drugs Market Forecast: CAGR (%) by Segment in 2014-2019, 2019-2025 and 2014-2025
Table 3.14 World Ophthalmic Drugs Market Forecast: Market Attractiveness ($m, CAGR%, Market Share%) by Segment, 2019
Table 3.15 World Ophthalmic Drugs Market Forecast: Market Attractiveness ($m, CAGR%, Market Share%) by Segment, 2025
Table 4.1 Allergan: Overview, 2015
Table 4.2 Allergan: Ophthalmic Drug Products, Revenue ($m), Growth Rate (%), 2014 and 2015
Table 4.3 Allergan: Restasis Revenue ($m), AGR (%), CAGR(%), 2014-2025
Table 4.4 Allergan: Lumigan and Ganfort Revenue ($m), AGR (%), CAGR(%), 2014-2025
Table 4.5 Allergan: Refresh Revenue ($m), AGR (%), CAGR(%), 2014-2025
Table 4.6 Allergan: Alphagan/Alphagan P and Combigan Revenue ($m), AGR (%), CAGR(%), 2014-2025
Table 4.7 Allergan: Acular Revenue ($m), AGR (%), CAGR(%), 2014-2025
Table 4.8 Allergan: Revenues ($m) and Revenue Shares (%) by Region, 2013
Table 4.9 Allergan: Ophthalmic Drugs Revenue ($m), AGR (%), CAGR(%), 2014-2025
Table 4.10 Allergan: Ophthalmic Drugs Market Share (%), Revenue ($m), 2014-2025
Table 4.11 Allergan: Ophthalmic Drugs Market SWOT Analysis, 2015-2025
Table 4.12 Merck: Overview, 2015
Table 4.13 Merck: Ophthalmic Drugs Revenue ($m), by Products in 2013 and 2014
Table 4.14 Pfizer: Overview, 2015
Table 4.15 Pfizer: Xalatan/Xalacom Revenue ($m), AGR (%), CAGR(%), 2014-2025
Table 4.16 Pfizer: Ophthalmic Drugs Revenue ($m), AGR (%), CAGR(%), 2014-2025
Table 4.17 Pfizer: Ophthalmic Drugs Market Share (%), Revenue ($m), 2014-2025
Table 4.18 Pfizer: Ophthalmic Drugs Market SWOT Analysis, 2015-2025
Table 4.19 Regeneron: Overview, 2015
Table 4.20 Regeneron: Eylea Revenue ($m), AGR (%), CAGR(%), 2014-2025
Table 4.21 Regeneron: Ophthalmic Drugs Revenue ($m), AGR (%), CAGR(%), 2014-2025
Table 4.22 Regeneron: Ophthalmic Drugs Market Share (%), Revenue ($m), 2014-2025
Table 4.23 Regeneron: Ophthalmic Drugs Market SWOT Analysis, 2015-2025
Table 4.24 Akorn: Overview, 2015
Table 4.25 Akorn: AzaSite Revenue ($m), AGR (%), CAGR(%), 2014-2025
Table 4.26 Akorn: Zioptan Revenue ($m), AGR (%), CAGR(%), 2014-2025
Table 4.27 Akorn: Cosopt and Cosopt PF Revenue ($m), AGR (%), CAGR(%), 2014-2025
Table 4.28 Akorn: Ophthalmic Drugs Revenue ($m), AGR (%), CAGR(%), 2014-2025
Table 4.29 Akorn: Ophthalmic Drugs Market Share (%), Revenue ($m), 2014-2025
Table 4.30 Akorn: Ophthalmic Drugs Market SWOT Analysis, 2015-2025
Table 5.1 Bayer: Overview, 2015
Table 5.2 Bayer: Eylea Revenue ($m), AGR (%), CAGR(%), 2014-2025
Table 4.3 Bayer: Ophthalmic Drugs Revenue ($m), AGR (%), CAGR(%), 2014-2025
Table 5.4 Bayer: Ophthalmic Drugs Market Share (%), Revenue ($m), 2014-2025
Table 5.5 Novartis: Overview, 2015
Table 5.6 Novartis: Lucentis Revenue ($m), AGR (%), CAGR(%), 2014-2025
Table 5.7 Novartis: Travatan/Travatan Z and DuoTrav Revenue ($m), AGR (%), CAGR(%), 2014-2025
Table 5.8 Novartis: Vigamox Revenue ($m), AGR (%), CAGR(%), 2014-2025
Table 5.9 Novartis: Azopt Revenue ($m), AGR (%), CAGR(%), 2014-2025
Table 5.10 Novartis: Jetrea Revenue ($m), AGR (%), CAGR(%), 2014-2025
Table 5.11 Novartis: Ophthalmic Drugs Revenue ($m), AGR (%), CAGR(%), 2014-2025
Table 5.12 Novartis: Ophthalmic Drugs Market Share (%), Revenue ($m), 2014-2025
Table 5.13 Novartis: Ophthalmic Drugs Market SWOT Analysis, 2015-2025
Table 5.14 Roche: Overview, 2015
Table 5.15 Roche: Lucentis Revenue ($m), AGR (%), CAGR(%), 2014-2025
Table 5.16 Roche: Avastin Revenue ($m), AGR (%), CAGR(%), 2014-2025
Table 5.17 Roche: Ophthalmic Drugs Revenue ($m), AGR (%), CAGR(%), 2014-2025
Table 5.18 Roche: Ophthalmic Drugs Market Share (%), Revenue ($m), 2014-2025
Table 5.19 Roche: Ophthalmic Drugs Market SWOT Analysis, 2015-2025
Table 6.1 Santen: Overview, 2015
Table 6.2 Santen: Revenue ($m) and Revenue Share (%) by Segment, 2013-2014
Table 6.3 Santen: Major Prescription Ophthalmic Drugs by Therapeutic Area, Launch Date, Region, 2014
Table 6.4 Santen: Major Prescription Ophthalmic Drugs, Revenue ($m), Revenue Share (%), 2014
Table 6.5 Santen: Eylea Revenue ($m), AGR (%), CAGR(%), 2014-2025
Table 6.6 Santen: Hyalein Revenue ($m), AGR (%), CAGR(%), 2014-2025
Table 6.7 Santen: Cosopt Revenue ($m), AGR (%), CAGR(%), 2014-2025
Table 6.8 Santen: Tapros/Taflotan Revenue ($m), AGR (%), CAGR(%), 2014-2025
Table 6.9 Santen: Diquas Revenue ($m), AGR (%), CAGR(%), 2014-2025
Table 6.10 Santen: Cravit Revenue ($m), AGR (%), CAGR(%), 2014-2025
Table 6.11 Santen: Trusopt Revenue ($m), AGR (%), CAGR(%), 2014-2025
Table 6.12 Santen: Ophthalmic Drugs Revenue ($m), AGR (%), CAGR(%), 2014-2025
Table 6.13 Santen: Ophthalmic Drugs Market Share (%), Revenue ($m), 2014-2025
Table 6.14 Santen: Ophthalmic Drugs Market SWOT Analysis, 2015-2025
Table 6.15 Senju: Overview, 2015
Table 6.16 Senju: Major Prescription Ophthalmic Drugs by Therapeutic Area, Launch Year, 2014
Table 6.17 Senju: Ophthalmic Drugs Revenue ($m), AGR (%), CAGR(%), 2014-2025
Table 6.18 Senju: Ophthalmic Drugs Market Share (%), Revenue ($m), 2014-2025
Table 6.19 Senju: Ophthalmic Drugs Market SWOT Analysis, 2015-2025
Table 6.20 Valeant: Overview, 2015
Table 6.21 Valeant: Timoptic Revenue ($m), AGR (%), CAGR(%), 2014-2025
Table 6.22 Valeant: Bromday Revenue ($m), AGR (%), CAGR(%), 2014-2025
Table 6.23 Valeant: Ophthalmic Drugs Revenue ($m), AGR (%), CAGR(%), 2014-2025
Table 6.24 Valeant: Ophthalmic Drugs Market Share (%), Revenue ($m), 2014-2025
Table 6.25 Valeant: Ophthalmic Drugs Market SWOT Analysis, 2015-2025
Table 7.1 Aerie Pharmaceuticals: Summary of Ophthalmic Drugs Pipeline, Clinical Phase, Intellectual Property Rights, 2015
Table 7.3 ThromboGenics: Jetrea Revenue ($m), AGR (%), CAGR(%), 2014-2025
Table 10.1 Leading Ophthalmic Drugs Manufacturers: Revenues ($m), 2014, 2019 and 2025

List of Figures
Figure 1.1 Global Causes of Visual Impairment (% of cases), 2012
Figure 1.2 World 65+ Population Forecast: Size (millions), CAGR (%), by National Market, 2014-2025
Figure 1.3 Global Ophthalmic Drugs Market Segmentation Overview, 2015
Figure 2.1 Estimated Global Prevalence of Visual Impairment (millions of people), 2012
Figure 2.2 Global Causes of Visual Impairment (% of cases), 2012
Figure 2.3 Classification of Glaucoma, 2015
Figure 3.1 World Ophthalmic Drugs Market: Revenues ($m) by Segment, 2014
Figure 3.2 World Ophthalmic Drugs Market Forecast: Revenue ($m), AGR (%), 2014-2025
Figure 3.3 Top 10 Ophthalmic Drugs: Revenues ($m), 2014
Figure 3.4 Top 10 Ophthalmic Drugs: Market Share (%), 2014
Figure 3.5 Top 10 Ophthalmic Drug Manufacturers: Ophthalmic Drugs Revenues ($m), 2014
Figure 3.6 Top 10 Ophthalmic Drug Manufacturers: Market Share (%), 2014
Figure 3.7 Retinal Disorders Drugs Market Forecast: Revenues ($m), 2014-2025
Figure 3.8 Allergic, Inflammatory and Infective Drugs Market Forecast: Revenues ($m), 2014-2025
Figure 3.9 Glaucoma Drugs Market Forecast: Revenues ($m), 2014-2025
Figure 3.10 Dry Eye Drugs Market Forecast: Revenues ($m), 2014-2025
Figure 3.11 Other Ophthalmic Drugs Market Forecast: Revenues ($m), 2014-2025
Figure 3.12 World Ophthalmic Drugs Market: Market Share (%) by Segment, 2014
Figure 3.13 World Ophthalmic Drugs Market Forecast: Market Shares (%) by Segment, 2019
Figure 3.14 World Ophthalmic Drugs Market Forecast: Market Shares (%) by Segment, 2025
Figure 3.15 World Ophthalmic Drugs Market Forecast: CAGR (%) by Segment in 2014-2019 and 2019-2025
Figure 3.16 World Ophthalmic Drugs Market Forecast: CAGR (%) by Segment in 2014-2025
Figure 3.17 World Ophthalmic Drugs Market Forecast: Market Attractiveness ($m, CAGR%) by Segment, 2019
Figure 3.18 World Ophthalmic Drugs Market Forecast: Market Attractiveness ($m, CAGR%) by Segment, 2025
Figure 3.19 World Ophthalmic Drugs Market: Drivers and Restraints, 2015-2025
Figure 4.1 Allergan: Restasis Revenue ($m), AGR (%), 2014-2025
Figure 4.2 Allergan: Lumigan and Ganfort Revenue ($m), AGR (%), 2014-2025
Figure 4.3 Allergan: Refresh Revenue ($m), AGR (%), 2014-2025
Figure 4.4 Allergan: Alphagan/Alphagan P and Combigan Revenue ($m), AGR (%), 2014-2025
Figure 4.5 Allergan: Acular Revenue ($m), AGR (%), 2014-2025
Figure 4.6 Allergan: Revenue Shares (%) by Region, 2013
Figure 4.7 Allergan: Ophthalmic Drugs Revenue ($m), AGR (%), 2014-2025
Figure 4.8 Allergan: Ophthalmic Drugs Market Share (%), 2014-2025
Figure 4.9 Pfizer: Xalatan/Xalacom Revenue ($m), AGR (%), 2014-2025
Figure 4.10 Pfizer: Ophthalmic Drugs Revenue ($m), AGR (%), 2014-2025
Figure 4.11 Pfizer: Ophthalmic Drugs Market Share (%), 2014-2025
Figure 4.12 Regeneron: Eylea Revenue ($m), AGR (%), 2014-2025
Figure 4.13 Regeneron: Ophthalmic Drugs Revenue ($m), AGR (%), 2014-2025
Figure 4.14 Regeneron: Ophthalmic Drugs Market Share (%), 2014-2025
Figure 4.15 Akorn: AzaSite Revenue ($m), AGR (%), 2014-2025
Figure 4.16 Akorn: Zioptan Revenue ($m), AGR (%), 2014-2025
Figure 4.17 Akorn: Cosopt and Cosopt PF Revenue ($m), AGR (%), 2014-2025
Figure 4.18 Akorn: Ophthalmic Drugs Revenue ($m), AGR (%), 2014-2025
Figure 4.19 Akorn: Ophthalmic Drugs Market Share (%), 2014-2025
Figure 5.1 Bayer: Eylea Revenue ($m), AGR (%), 2014-2025
Figure 5.2 Bayer: Ophthalmic Drugs Revenue ($m), AGR (%), 2014-2025
Figure 5.3 Bayer: Ophthalmic Drugs Market Share (%), 2014-2025
Figure 5.4 Novartis: Lucentis Revenue ($m), AGR (%), 2014-2025
Figure 5.5 Novartis: Travatan/Travatan Z and DuoTrav Revenue ($m), AGR (%), 2014-2025
Figure 5.6 Novartis: Vigamox Revenue ($m), AGR (%), 2014-2025
Figure 5.7 Novartis: Azopt Revenue ($m), AGR (%), 2014-2025
Figure 5.8 Novartis: Jetrea Revenue ($m), AGR (%), 2014-2025
Figure 5.9 Novartis: Ophthalmic Drugs Revenue ($m), AGR (%), 2014-2025
Figure 5.10 Novartis: Ophthalmic Drugs Market Share (%), 2014-2025
Figure 5.11 Roche: Lucentis Revenue ($m), AGR (%), 2014-2025
Figure 5.12 Roche: Avastin Revenue ($m), AGR (%), 2014-2025
Figure 5.13 Roche: Ophthalmic Drugs Revenue ($m), AGR (%), 2014-2025
Figure 5.14 Roche: Ophthalmic Drugs Market Share (%), 2014-2025
Figure 6.1 Santen: Ophthalmic Drugs Revenue ($m) by Segment, 2013-2014
Figure 6.2 Santen: Major Prescription Ophthalmic Drugs, Revenue Share (%), 2014
Figure 6.3 Santen: Eylea Revenue ($m), AGR (%), 2014-2025
Figure 6.4 Santen: Hyalein Revenue ($m), AGR (%), 2014-2025
Figure 6.5 Santen: Cosopt Revenue ($m), AGR (%), 2014-2025
Figure 6.6 Santen: Tapros/Taflotan Revenue ($m), AGR (%), 2014-2025
Figure 6.7 Santen: Diquas Revenue ($m), AGR (%), 2014-2025
Figure 6.8 Santen: Cravit Revenue ($m), AGR (%), 2014-2025
Figure 6.9 Santen: Trusopt Revenue ($m), AGR (%), 2014-2025
Figure 6.10 Santen: Ophthalmic Drugs Revenue ($m), AGR (%), 2014-2025
Figure 6.11 Santen: Ophthalmic Drugs Market Share (%), 2014-2025
Figure 6.12 Senju: Ophthalmic Drugs Revenue ($m), AGR (%), 2014-2025
Figure 6.13 Senju: Ophthalmic Drugs Market Share (%), 2014-2025
Figure 6.14 Valeant: Timoptic Revenue ($m), AGR (%), 2014-2025
Figure 6.15 Valeant: Bromday Revenue ($m), AGR (%), 2014-2025
Figure 6.16 Valeant: Ophthalmic Drugs Revenue ($m), AGR (%), 2014-2025
Figure 6.17 Valeant: Ophthalmic Drugs Market Share (%), 2014-2025
Figure 7.1 Alimera Sciences: Ophthalmic Drug Pipeline Progress, 2015
Figure 7.2 Gene Signal: Ophthalmic Drug Pipeline Progress, 2015
Figure 7.3 Neurotech: Ophthalmic Drug Pipeline Progress, 2015
Figure 7.4 Ophthotech: Ophthalmic Drug Pipeline Progress, 2015
Figure 7.2 Otsuka Pharmaceutical: Overview of Ophthalmic Drug Pipelines, Drug Type, Indication, Country, 2015
Figure 7.5 Otsuka Pharmaceutical: Ophthalmic Drug Pipeline Progress, 2015
Figure 7.6 Shire: Ophthalmic Drug Pipeline Progress, 2015
Figure 7.7 ThromboGenics: Jetrea Revenue ($m), AGR (%), 2014-2025
Figure 8.1 Porter’s Five Forces Analysis of the Ophthalmic Drugs Market, 2015-2025
Figure 10.1 Leading Ophthalmic Drugs Manufacturers: Revenues ($m), 2014, 2019 and 2025

【レポートのキーワード】

眼薬メーカー、網膜障害、緑内障、ドライアイ、アレルギー性・炎症性疾患・感染症、眼疾患治療薬、市場規模、製薬企業

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の眼疾患治療薬分野における主要な製薬企業分析(Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆